Last reviewed · How we verify

Kurobe LLC — Portfolio Competitive Intelligence Brief

Kurobe LLC pipeline: 0 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 1 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Vancomycin 1.1% Vancomycin 1.1% phase 3 glycopeptide antibiotic D-alanyl-D-alanine terminus of cell wall precursors Infectious Disease

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Astellas Pharma Europe B.V. · 1 shared drug class
  2. Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · 1 shared drug class
  3. Major Extremity Trauma Research Consortium · 1 shared drug class
  4. Savara Inc. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Kurobe LLC:

Cite this brief

Drug Landscape (2026). Kurobe LLC — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/kurobe-llc. Accessed 2026-05-14.

Related